The US Centers for Disease Control and Prevention (CDC) have recommended Merck’s ENFLONSIA as a preventive treatment for infants under 8 months who are born during or enter their first season of Respiratory Syncytial Virus (RSV).
ENFLONSIA is an immunoglobulin-based medication that targets RSV and helps to protect against severe respiratory infections, such as bronchiolitis and pneumonia. According to the CDC, two out of every 100 infants under six months old are hospitalized with RSV annually.
This recommendation comes after extensive clinical trials and real-world data showed ENFLONSIA’s effectiveness in preventing severe RSV disease in infants at high risk. The medication is administered as a single dose, which reduces the need for repeated injections compared to other existing treatments.
However, it is essential to note that ENFLONSIA should only be used by individuals with a confirmed history of serious hypersensitivity reactions or anaphylaxis to any component of the medication. Side effects such as injection-site erythema and swelling have been reported in clinical trials but are generally mild and temporary.
Merck & Co., Inc. (the manufacturer) has issued a statement acknowledging that there is no guarantee of regulatory approval for ENFLONSIA candidates or their commercial success.
Source: https://www.merck.com/news/acip-recommends-use-of-mercks-enflonsia-clesrovimab-cfor-for-prevention-of-respiratory-syncytial-virus-rsv-lower-respiratory-tract-disease-in-infants-younger-than-8-months-of-age